Dose-dense treatment with gemcitabine, epirubicin and paclitaxel GET combination in advanced breast cancer a phase II parallel study
- Conditions
- Women with advanced metastatic breast cancer, not previously treated with anthracyclines or taxanesMedDRA version: 6.1Level: HLTClassification code 10006292
- Registration Number
- EUCTR2005-003582-16-IT
- Lead Sponsor
- AZIENDA OSPEDALIERA POLICLINICO DI MODENA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie gemcitabine, epirubicin, and paclitaxel synergy in advanced breast cancer?
How does dose-dense GET regimen compare to standard anthracycline-taxane combinations in metastatic breast cancer outcomes?
Which biomarkers (e.g., ER, PR, HER2, Ki-67) correlate with response to dose-dense GET in anthracycline/taxane-naive patients?
What are the safety profiles and management strategies for myelosuppression or neuropathy in dose-dense GET trials?
Are there alternative taxane-based combinations (e.g., nab-paclitaxel) with gemcitabine for metastatic breast cancer treatment?